AstraZeneca terminates agreement with Map Pharma
This article was originally published in Scrip
Executive Summary
AstraZeneca has terminated a licence agreement to develop Map Pharmaceuticals' unit dose budesonide (UDB), an agreement that was worth up to $900 million.